Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Talebian Yazdi, Mehrdad ^a   Schinkelshoek, Mink S ^a   Loof, Nikki M ^a   Taube, Christian ^a   Hiemstra, Pieter S ^a   Welters, Marij J P ^a   van der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; immunity; immunotherapy; myeloid cells; radiotherapy; T cells

Indexed keywords

CARBOPLATIN; NAVELBINE; PEMETREXED;

ADULT; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LYMPHOCYTOPENIA; MALE; MIXED LYMPHOCYTE REACTION; NON SMALL CELL LUNG CANCER; PROSPECTIVE STUDY; RADIATION DOSE;

EID: 85006312422     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1255393     Document Type: Article

References (33)

1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer:recent developments. Lancet 2013; 382:709-19; PMID:23972814; http://dx.doi.org/10.1016/S0140-6736(13)61502-0
2. de Castria TB, da Silva EM, Gois AF, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2013; 8:CD009256; PMID:23949842; http://dx.doi.org/10.1002/14651858.CD009256.pub2
3. Viteri S, Gonzalez-Cao M, Barron F, Riso A, Rosell R. Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. Transl Lung Cancer Res 2015; 4:756-62; PMID:26798585; http://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.06
4. Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation:rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother 2015; 65:779-86; PMID:26590829; http://dx.doi.org/10.1007/s00262-015-1771-8
5. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally:immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
6. Gupta A, Sharma A, von Boehmer L, Surace L, Knuth A, van den Broek M. Radiotherapy supports protective tumor-specific immunity. Oncoimmunology 2012; 1:1610-1; PMID:23264910; http://dx.doi.org/10.4161/onci.21478
7. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer:overcoming the challenges posed by immune evasion. Nat Rev Cancer 2016; 16:219-33; PMID:26965076; http://dx.doi.org/10.1038/nrc.2016.16
8. Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways:the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 2014; 20:2831-7; PMID:24879823; http://dx.doi.org/10.1158/1078-0432.CCR-13-3141
9. Okita R, Yukawa T, Nojima Y, Maeda A, Saisho S, Shimizu K, Nakata M. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer. Cancer Immunol Immunother 2016; 65:499-509; PMID:26940474; http://dx.doi.org/10.1007/s00262-016-1814-9
10. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Pruschy M, Knuth A, van den Broek M. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol 2012; 189:558-66; PMID:22685313; http://dx.doi.org/10.4049/jimmunol.1200563
11. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011; 71:2488-96; PMID:21300764; http://dx.doi.org/10.1158/0008-5472.CAN-10-2820
12. Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, Knuth A, Boehmer Lv, Broek Mv. gamma-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PloS One 2011; 6:e28217; PMID:22140550; http://dx.doi.org/10.1371/journal.pone.0028217
13. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer:looking to the future. J Clin Oncol 2005; 23:3175-85; PMID:15886304; http://dx.doi.org/10.1200/JCO.2005.10.462
14. Talebian Yazdi M, Loof NM, Franken KL, Taube C, Oostendorp J, Hiemstra PS, Welters MJ, van der Burg SH. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma. Cancer Immunol Immunother 2015; 64:1109-21; PMID:26025564; http://dx.doi.org/10.1007/s00262-015-1716-2
15. Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med 2016; 8:334ra52; PMID:27075626; http://dx.doi.org/10.1126/scitranslmed.aad8307
16. Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget 2015; 6:32228-43; PMID:26334096; http://dx.doi.org/10.18632/oncotarget.4772
17. Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, et al. Monitoring regulatory T cells in clinical samples:consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother 2015; 64:1271-86; PMID:26122357; http://dx.doi.org/10.1007/s00262-015-1729-x
18. Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry:results from an interim study. Cancer Immunol Immunother 2016; 65:161-9; PMID:26728481; http://dx.doi.org/10.1007/s00262-015-1782-5
19. Vuckovic-Dekic L, Susnjar S, Stanojevic-Bakic N, Radosavljevic D. Radio- and chemotherapy variably affect the general immunocompetence of lung cancer patients. Panminerva Med 1999; 41:129-33; PMID:10479911
20. Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996; 14:1071-6; PMID:8648359; http://dx.doi.org/10.1200/jco.1996.14.4.1071
21. Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 2013; 31:183-8; PMID:23432821; http://dx.doi.org/10.3109/07357907.2013.767342
22. Grossman SA, Ellsworth S, Campian J, Wild AT, Herman JM, Laheru D, Brock M, Balmanoukian A, Ye X. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Cancer Netw 2015; 13:1225-31; PMID:26483062
23. Yovino S, Grossman SA. Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol 2012; 1:149-54; PMID:23828734; http://dx.doi.org/10.2217/cns.12.14
24. Belka C, Ottinger H, Kreuzfelder E, Weinmann M, Lindemann M, Lepple-Wienhues A, Budach W, Grosse-Wilde H, Bamberg M. Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol 1999; 50:199-204; PMID:10368044; http://dx.doi.org/10.1016/S0167-8140(98)00130-3
25. van Rijswijk RE, Sybesma JP, Kater L. A prospective study of the changes in immune status following radiotherapy for Hodgkin's disease. Cancer 1984; 53:62-9; PMID:6690004; http://dx.doi.org/10.1002/1097-0142(19840101)53:1%3c62::AID-CNCR2820530112%3e3.0.CO;2-3
26. van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, Boon L, Smit VT, Welters MJ, Ossendorp F, et al. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin Cancer Res 2015; 21:781-94; PMID:25501579; http://dx.doi.org/10.1158/1078-0432.CCR-14-2142
27. Beyranvand Nejad E, van der Sluis TC, van Duikeren S, Yagita H, Janssen GM, van Veelen PA, Melief CJ, van der Burg SH, Arens R. Tumor eradication by cisplatin is sustained by CD80/86-mediated costimulation of CD8+ T cells. Cancer Res 2016; 76(20):6017-29; PMID:27569212; http://dx.doi.org/10.1158/0008-5472.CAN-16-0881
28. Schulof RS, Chorba TL, Cleary PA, Palaszynski SR, Alabaster O, Goldstein AL. T-cell abnormalities after mediastinal irradiation for lung cancer. The in vitro influence of synthetic thymosin alpha-1. Cancer 1985; 55:974-83; PMID:3155644; http://dx.doi.org/10.1002/1097-0142(19850301)55:5<974
29. van Baardwijk A, Tome WA, van Elmpt W, Bentzen SM, Reymen B, Wanders R, Houben R, Ollers M, Lambin P, De Ruysscher D. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol 2012; 105:145-9; PMID:23068707; http://dx.doi.org/10.1016/j.radonc.2012.09.008
30. Wang S, Fu Y, Ma K, Liu C, Jiao X, Du W, Zhang H, Wu X. The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients. Clin Transl Oncol 2014; 16:616-22; PMID:24193866; http://dx.doi.org/10.1007/s12094-013-1125-y
31. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(−)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136:35-45; PMID:19572148; http://dx.doi.org/10.1007/s00432-009-0634-0
32. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 2005; 175:2684-91; PMID:16081845; http://dx.doi.org/10.4049/jimmunol.175.4.2684
33. Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003; 109:365-73; PMID:12807482; http://dx.doi.org/10.1046/j.1365-2567.2003.01655.x